Company intelligence / Profile preview

MetaboGen

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

MetaboGen has developed a proprietary platform integrating metagenomic analysis with strain identification to create next-generation probiotics. The company has conducted at least two clinical trials and holds several patents related to bacteriology, biotechnology, and combination drugs. As a wholly owned subsidiary of BioGaia AB since acquisition, it focuses on research and product development targeting the human microbiome for innovative probiotic products.

No detailed public results from specific clinical studies are available.

Therapeutic areas: GastroenterologyOther
Modalities: Next-generation probioticsmicrobiome-based therapeutics
Industry: Biotech

Partnerships

Parent company BioGaia AB

Beyond the preview

Go deeper on MetaboGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MetaboGen.

Explore the full profile